Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of E2730 in Healthy Subjects
NCT04676685Phase 1Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Dec 2020
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of E2730 in epilepsy (6 arms), sponsored by Eisai Co., Ltd. Primary endpoints: Number of Participants With Treatment-emergent Adverse Events at Day 32, Maximum Observed Plasma Concentration for E2730 at Day 22 and 3 more. Started Dec 2020; status: completed.
02
Drugs
E2730
03
Conditions
epilepsy
Beyond the preview
Go deeper on NCT04676685.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04676685.